Ascentage Pharma Group International (HKG:6855)

Market Cap	15.74B +19.8%
Revenue (ttm)	638.89M -41.5%
Net Income	-1.38B
EPS	-3.88
Shares Out	368.05M
PE Ratio	n/a
Forward PE	34.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,342,400
Average Volume	2,289,679
Open	42.68
Previous Close	42.76
Day's Range	42.26 - 46.48
52-Week Range	31.35 - 95.35
Beta	0.87
RSI	50.87
Earnings Date	Mar 25, 2026

About HKG:6855

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 605
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6855

Financial Performance

In 2025, HKG:6855's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.

Financial numbers in CNY